Pharmacological treatment of chorea in Huntington's disease-good clinical practice versus evidence-based guideline

Area of Science:

• Neurology
• Clinical Pharmacology

Background:

• The American Academy of Neurology (AAN) recently released a guideline for treating chorea in Huntington's disease (HD).
• The guideline's evidence levels are based on arbitrary anchors in the Unified Huntington's Disease Rating Scale-Total Motor Score chorea sum score.
• These anchors may not reflect clinically relevant or validated measures of chorea severity.

Purpose of the Study:

• To critically review the limitations of the AAN guideline for chorea in Huntington's disease.
• To argue against the adoption of the guideline's recommendations due to their lack of clinical relevance.
• To propose an alternative, pragmatic treatment pathway for chorea in HD.

Main Methods:

• Critical analysis of the AAN guideline's methodology and recommendations.
• Review of current clinical practices for managing chorea in Huntington's disease.
• Development of an expert-opinion-based flow-chart for symptomatic therapy.

Main Results:

• The AAN guideline's evidence classification for chorea treatments is based on arbitrary and clinically irrelevant metrics.
• The guideline's recommendations do not align with current clinical practice for managing chorea in Huntington's disease.
• A novel flow-chart is presented to guide pragmatic, expert-endorsed symptomatic therapy for chorea in HD.

Conclusions:

• The AAN guideline for chorea in Huntington's disease has significant limitations and should not be followed.
• Current clinical practice relies on expert opinion and validated clinical relevance for treatment decisions.
• An expert-driven flow-chart offers a more pragmatic approach to symptomatic chorea management in HD.